US Pharma Reshoring: The Full Policy Timeline

By Dora Wells, Editor of PharmaSource and Conference Produce

Pharmaceutical reshoring in the United States has moved from a policy discussion to a complex mix of trade, regulatory, industrial, and supply chain initiatives. Since 2025, policymakers have introduced tariffs, manufacturing incentives, FDA programs designed to accelerate domestic production, Most Favored Nation pricing agreements, and proposals aimed at strengthening oversight of foreign influence across the drug supply chain. Together, these measures have sparked hundreds of billions of dollars in announced investments and renewed focus on supply chain resilience.

Yet significant questions remain about how much production can realistically move back to the U.S. Industry leaders point to persistent challenges, including limited manufacturing capacity, workforce shortages, long facility construction timelines, and continued dependence on overseas sources of active pharmaceutical ingredients and key starting materials. For generic medicines in particular, cost pressures and uncertain long-term demand continue to complicate reshoring efforts.

As implementation replaces policy announcements, success will be measured less by investment headlines and more by qualified capacity, diversified supply networks, and sustainable domestic production. Explore the full policy timeline and expert perspectives shaping the future of U.S. pharmaceutical manufacturing and supply chain resilience.